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Enterobacterial isolates expressing the carbapenemase NDM-1 are emerging worldwide. Twenty-seven
NDM-1-positive isolates of worldwide origin were included in this study to identify these strains as not only
pathogens but also colonizers of normal flora for infection control screening. Although susceptibility to
carbapenems varied, a combined test (IMP/IMP  EDTA), the Etest MBL, and automated susceptibility
testing by Vitek2 (bioMe´rieux) identified those NDM-1 producers as verified by PCR using specific primers.
Screening for carriers of NDM-1 producers may be based on media such as the ChromID ESBL culture
medium routinely used to screen for extended-spectrum -lactamase producers, which gives excellent detection
levels with low limits of detection ranging from 8  100 to 5  102 CFU/ml. The CHROMagar KPC culture
medium had higher limits of detection (1  101 to 5  105 CFU/ml) and may be proposed for the follow-up of
outbreaks of infections with NDM-1 producers. Colonies growing on these screening media can be verified as
NDM-1 producers with molecular methods as described herein.
NDM-1 is a broad-spectrum -lactamase (carbapen-
emase) that is able to inactivate all -lactams except aztreo-
nam (18). However, most NDM-1-positive strains also ex-
press the CMY-4 and CTX-M-15 -lactamases, which confer
resistance to all -lactams (8). Although discovered in 2008,
NDM-1-positive Enterobacteriaceae have attracted worldwide
media attention due to their high incidence in India and be-
cause many United Kingdom isolates can be directly tracked to
India and Pakistan (5, 8). Several reports indicate further
spread of this resistance determinant worldwide, including in
the United States (three isolates [3]) and Australia (11), with
relationships in most of the cases with the Indian subcontinent.
In contrast to many other resistance mechanisms, NDM-1 is
not associated with a single strain but has spread very rapidly
to non-clonally related isolates (8). It has been identified
mostly in Escherichia coli and Klebsiella pneumoniae and to a
lesser degree in other enterobacterial species (5, 8). Plasmids
carrying the blaNDM-1 gene also carry a number of other genes
conferring resistance to all aminoglycosides, macrolides, and
sulfamethoxazole, thus making these isolates multidrug resis-
tant or, because of other non-plasmid-mediated resistances,
resistant in some cases to all antibiotics, including tigecycline
and colistin (8). Although carbapenemase-producing Entero-
bacteriaceae isolates have been increasingly identified world-
wide, such as K. pneumoniae carbapenemase (KPC) producers
(9, 10), NDM-1 producers bring several additional factors
which are deeply disconcerting for public health worldwide.
First, the blaNDM-1 gene has been identified in not a single
species but in unrelated species (including Acinetobacter spp.
[7]), indicating that this gene can spread at an unprecedented
rate. Second, it is present not only in K. pneumoniae, a typical
nosocomial pathogen, but also in E. coli, which is also a major
community-acquired pathogen. Third, E. coli is also the num-
ber one cause of diarrhea in children in India and Pakistan,
increasing the risk of resistant strains being released into the
environment, and the blaNDM-1 gene is primarily from the
Indian subcontinent, which has the second largest population
in the world (1.3 billion people). Overpopulation, lack of basic
sanitation and access to clean water, a tropical climate (the
southern part of the peninsula), and poor control of antibiotic
use are all compounding factors that may promote the transfer
of NDM-1-positive bacteria among the populations of India
and Pakistan and then internationally. Therefore, there is an
urgent international need to detect NDM-1 producers in any
health care facility to prevent their further spread.
We report here several techniques for the detection of
NDM-1 producers—whether for managing clinical infections
or screening for colonizers. We have gathered a collection of
international nonclonal strains, including several enterobacte-
rial species demonstrating various susceptibilities to carbapen-
ems, which were used to assess these methods (Table 1).
Identification of NDM-1 producers. Susceptibility testing
was performed by determining MICs by Etest (AB bioMe´rieux,
Solna, Sweden) on Mueller-Hinton agar plates at 37°C, and
results of susceptibility testing were recorded according to the
CLSI guidelines as modified in June 2010 (4). The breakpoints
for imipenem are as follows: susceptible (S), 1 g/ml; resis-
tant (R), 4 g/ml. Those for meropenem are as follows: S,
1 g/ml; R,4 g/ml. Those for ertapenem are as follows: S,
0.25 g/ml; R, 1 g/ml. Those for doripenem are as fol-
lows: S, 1 g/ml; R, 4 g/ml. Twenty-six of the 27 NDM-1
strains were resistant to at least one carbapenem, and 8 were
resistant only to ertapenem (Table 1). A single isolate (Provi-
dencia rettgeri A) was only of intermediate susceptibility to
imipenem and ertapenem (Table 1). Various susceptibilities to
carbapenems have been reported for producers of other types
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of carbapenemases, such as KPC and VIM producers (9, 10,
12, 15), particularly E. coli. Ertapenem has also been proposed
to be a most appropriate carbapenem for detecting KPC pro-
ducers with low-level resistance to carbapenems (2, 15) and
also seems to be the most appropriate carbapenem for detect-
ing NDM-1 producers.
The Etest MBL strip is one of the methods advocated for
detecting metallo--lactamase (MBL) producers based on in-
hibition of MBL activity by EDTA (16). The Etest MBL using
imipenem and imipenem-EDTA was reliable for their detec-
tion, except in two cases (Enterobacter cloacae D and K. pneu-
moniae E), in which interpretation of the results was not pos-
sible because the imipenem MICs were too low (Table 1).
Therefore, we have evaluated another technique, the com-
bined disk test, which is also based on inhibition of MBL
activity by EDTA (6). Two imipenem disks (10 g), one con-
taining 10 l of 0.1 M anhydrous EDTA (292 g), were placed
25 mm apart on a Mueller-Hinton plate (6). A strain producing
a diameter of 4 mm around the disk with IMP-EDTA and
not around the disk with IMP alone was considered positive for
MBL. All 27 NDM-1 producers were positively detected by this
technique (Table 1), which is reliable for detecting MBL pro-
ducers on a daily basis. The Etest MBL may be used in labs
which do not screen for MBL producers on a daily basis or in
those which perform susceptibility testing using liquid medium
techniques and rarely use disk diffusion susceptibility tech-
niques.
The collection of NDM-1 producers was then examined by
a commercial automated system designed for antibiotic sus-
ceptibility testing, Vitek 2 (expert system version 04.02; bio-
Me´rieux, La-Balme-Les-Grottes, France). The tested carbap-
enem in card AST-N128 is imipenem, with breakpoints of 2
g/ml for susceptibility and 8 g/ml for resistance. All
NDM-1 producers had MICs of imipenem by Vitek2 that were
higher than those obtained by the Etest method. They were of
intermediate susceptibility or resistant to carbapenems and
TABLE 1. Sensitivity of detection of 27 NDM-1 producers by ChromID ESBL and CHROMagar KPC media, results of the combined disk
testa and the Etest MBL, and MICs of several -lactams
Isolate Country ofisolation
MIC (g/ml)b
Etest
MBL
IMP/IMP 
EDTA
Lower limit of detection
(CFU/ml)
CTX CAZ IMP ETP MER DOR ChromIDESBL
CHROMagar
KPC
E. coli
A Australia 32 256 6 4 4 32   2  101 3  101
B France 32 256 3 3 2 2   2  101 3  105
C India 32 256 2 32 24 6   3  101 3  101
D India 32 256 16 32 16 3   1  101 1  101
E India 32 256 32 32 32 24   2  102 1  101
F India 32 256 32 32 16 16   1  101 3  101
G India 32 256 4 32 8 3   3  101 4  101
H India 32 256 1.5 8 2 1   1  101 2  105
I India 32 256 3 32 6 2   1  101 1  101
J India 32 256 2 4 2 1.5   8  100 1  104
E. cloacae
A India 32 256 8 6 6 4   1  101 5  101
B India 32 256 32 12 8 12   1  101 1  101
C India 32 256 2 16 2 1   3  102 4  104
D India 32 256 0.75 3 1.5 1 —c  1  101 1  102
K. pneumoniae
A Kenya 32 256 32 32 32 32   2  101 1  101
B Sultanate of
Oman
32 256 32 32 32 32   1  101 2  101
C Sultanate of
Oman
32 256 1 6 2 2   1  101 3  102
D India 32 256 32 32 32 32   2  101 3  101
E India 32 256 0.75 8 2 1.5 —  1  101 3  102
F India 32 256 32 32 32 32   1  101 8  101
G India 32 256 2 6 2 1.5   1  101 1  102
H India 32 256 32 32 32 32   1  101 5  102
I India 32 256 32 32 32 32   1  101 5  102
J India 32 256 6 32 16 12   1  101 1  101
K. oxytoca A India 32 256 2 4 3 3   1  101 1  104
C. freundii A France 32 256 32 32 32 32   1  101 1  101
P. rettgeri A India 32 256 3 0.5 1.5 0.75   5  102 5  105
a IMP, IMP plus EDTA.
b CTX, cefotaxime; CAZ; ceftazidime; IMP, imipenem; ETP, ertapenem; MER, meropenem; DOR, doripenem.
c —, not interpretable.
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were flagged as producers of carbapenemases. Our data mirror
and extend the results obtained in another study that evaluated
three automated systems, BD Phoenix (BD Diagnostics), Mi-
croscan (Siemens), and Vitek 2 (bioMe´rieux), for the detection
and inference of mechanisms responsible for carbapenem re-
sistance in carbapenem-resistant Enterobacteriaceae (17). That
study included six NDM-1 producers likely of United Kingdom
origin (17).
Although carbapenemase detection by spectrophotometric
assay has been suggested for detecting carbapenemase produc-
ers (10, 17) and the results were positive for all of the NDM-1
producers we tested here (data not shown), we do not recom-
mend this method on a routine basis as it is time-consuming
and does not discriminate between NDM-1 and other MBLs.
Similarly, we do not recommend MBL activity detection by the
Hodge test, which is not only time-consuming but may also lack
specificity (15). Finally, the detection of the blaNDM-1 gene
based on a PCR molecular technique was established. The prim-
ers assessed in this study were NDM-Fm (5-GGTTTGGCGAT
CTGGTTTTC-3, positions 133 to 153) and NDM-Rm (5-CGG
AATGGCTCATCACGATC-3, positions 734 to 754), which
amplified an internal fragment of 621 bp of the blaNDM-1 gene.
Primers were designed according to the sequence of the
blaNDM-1 gene in the GenBank database under accession no.
FN392876. Total DNA was extracted from bacterial isolates by
alkaline lysis. Negative controls included reference strains pro-
ducing the MBL blaIMP, blaVIM, blaSPM, blaGIM, and blaSIM
genes. Two microliters of extracted total DNA was subjected
to PCR in a 50-l reaction mixture. The PCR mixture for the
detection of MBL genes contained 1 PCR buffer (10 mM
Tris-HCl [pH 8.3], 50 mM KCl), 1.5 mM MgCl2, 0.125 mM
each deoxynucleotide triphosphate, 0.1 M each primer, and 2
U of AmpliTaq Gold polymerase (Roche, Meylan, France).
Amplification was carried out under the following thermal
cycling conditions: 10 min at 94°C; 36 cycles of amplification
consisting of 30 s at 94°C, 40 s at 52°C, and 50 s at 72°C; and
5 min at 72°C for the final extension. DNA fragments were
visualized by electrophoresis in a 2% agarose gel at 100 V for
1 h in 1 TAE (40 mM Tris-HCl [pH 8.3], 2 mM acetate, 1
mM EDTA) containing 0.05 mg/liter ethidium bromide. Using
this technique, the blaNDM-1-positive isolates were detected
within less than 3 h with 100% sensitivity and excellent speci-
ficity, as deduced by testing a few reference strains expressing
other types of carbapenemase genes (data not shown).
Screening for carriers of NDM-1 producers. Efficient pre-
vention of the spread of NDM-1 producers requires a rapid
screening method that can detect NDM-1 producers as colo-
nizers (mostly in the gastrointestinal tract) when the carrier
patient is admitted to any health care facility. We have shown
recently that the screening culture medium ChromID ESBL
culture medium (bioMe´rieux) containing cefpodoxime as a
selector, which is routinely used to screen for extended-spec-
trum -lactamase (ESBL) producers (13), may also be used to
detect carbapenemase-producing Enterobacteriaceae (1). This
culture medium may also provide a preliminary bacterial iden-
tification (E. coli; K. pneumoniae, etc.) at the species level
based on the differential chromogenic properties of the enter-
obacterial species (13). Producers of IMP-, VIM-, and KPC-
type carbapenemases with high-level resistance to cephalospo-
rins and carbapenems were easily detected by ChromID ESBL
(1, 13). In this same study, we had evaluated another screening
medium, CHROMagar KPC (CHROMagar Company, Paris,
France), which contains a carbapenem as the selector for re-
sistance and was first specifically designed for screening for
KPC producers (1, 14). Using the CHROMagar medium, car-
bapenemase-producing isolates with MICs of 4 g/ml were
detected with much higher detection limits (1).
Since NDM-1 producers were not included in that study, we
have now evaluated both screening media using our collection
of NDM-1 producers. An inoculum of 2  106 (range, 1.5 
105 to 3.5  107) CFU/ml was used, serial 10-fold dilutions
were made in normal saline buffer, and then 100 l was plated
onto sheep blood-containing tryptic soy agar, ChromID ESBL
medium, and CHROMagar KPC medium. Viable bacteria
were counted after 24 and 48 h of culture at 37°C, and growth
on selective medium was compared to growth on standard
culture medium. The lower limit of detection of NDM-1
producers ranged from 8  100 to 5  102 CFU/ml for
ChromID ESBL (Table 1). The ability of that medium to
detect NDM-1 producers is based on the fact that those
producers are also resistant to expanded-spectrum cephalo-
sporins, in part due to the broad-spectrum hydrolytic prop-
erties of the -lactamase NDM-1 (Table 1). Therefore, this
detection was possible using ChromID ESBL even though the
strain may not express an ESBL (E. coli B, for example [data
not shown]). For CHROMagar KPC, the lower limit of detec-
tion of NDM-1 producers ranged from 1  101 to 4  105
CFU/ml (Table 1). Those detection limits were higher than
those of the ChromID ESBL medium, especially for several
strains with low MICs of carbapenems (E. coli B, E. coli H, E.
coli J, E. cloacae C, Klebsiella oxytoca A, Providencia rettgeri A).
After the screening of putative NDM-1 producers, definitive
identification of the NDM-1 producers is needed using the
techniques developed above (susceptibility testing, Etest, and
PCR) (Fig. 1). This detection strategy may help to prevent the
development of clinically significant outbreaks of infections
with NDM-1-positive clinical isolates, in particular NDM-1 K.
pneumoniae.
Conclusion. Early identification of NDM-1 producers in
bacteria causing clinical infections and/or colonizers is manda-
tory to prevent their spread. Identification of NDM-1 produc-
ers in clinical infections will be suspected on any decreased
susceptibility to carbapenems in Enterobacteriaceae, especially
in E. coli, where resistance to carbapenems may not always be
apparent. The ChromID ESBL is a reliable culture medium for
screening for carriers of NDM-1 producers. Since ChromID
ESBL may also detect ESBL producers, its use for detecting
carbapenemase producers may be the source of an extra work
load. However, the higher sensitivity of ChromID ESBL than
CHROMagar argues for its use. In addition, ChromID ESBL
offers the economical advantage of using a single plate to
detect ESBL and carbapenemase producers.
CHROMagar culture medium may be proposed for the fol-
low-up of an outbreak of NDM-1 producers after identification
of the first cases using ChromID ESBL and after checking that
this medium is sensitive enough to detect the specific NDM-1
producer strain responsible for the outbreak. We believe that
a screening strategy based on early detection of NDM-1
producers for any international transfer of hospitalized pa-
tients on a worldwide scale and for at-risk patients in areas
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of endemicity may prevent outbreaks of infections with
NDM-1 producers.
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FIG. 1. Strategy for identification of NDM-1 producers as a source
of clinical infections and for detecting carriers of NDM-1 producers. *,
this culture medium can be used for surveillance of outbreaks of
infections with NDM-1 producers after validation of its detection sen-
sitivity for the specific strain responsible for an outbreak. **, Etest
MBL is reliable when the MIC of imipenem is not too low.
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